25: Thoracic Flashcards
Which pulmonary nodes are not assessed by mediastinascopy
Aorto-pulmonary (AP) window nodes (left lung drainage)
[UpToDate: SCM can easily access pretracheal (1, 3), paratracheal (2R, 2L, 4R, 4L), anterior subcarinal (7) and occasionally hilar (10) nodes. It is not able to sample subaortic (5) or para-aortic (6), inferior (8, 9), posterior subcarinal (7), or lobar/interlobar (11 to 14) stations. Use of the video mediastinoscope can extend access to the posterior subcarinal nodes (station 7). SCM is best used to sample lymph nodes in these selected stations, particularly when other staging modalities have failed or are not available.]
What is the difference between the granulomas seen in tuberculosis and sarcoidosis?
- TB = Caseating granulomas
- Sarcoidosis = Non-caseating granulomas
[Wikipedia: “caseation” (literally: turning to cheese) refers to a form of necrosis that, to the unaided eye (i.e., without a microscope), appears cheese-like (“caseous”), and is typically (but not uniquely) a feature of the granulomas of tuberculosis. The identification of necrosis in granulomas is important because granulomas with necrosis tend to have infectious causes.]
[UpToDate: Microscopy of tissue biopsy specimens in the setting of tuberculosis typically demonstrates granulomatous inflammation. Granulomas of tuberculosis characteristically contain epithelioid macrophages, Langhans giant cells, and lymphocytes. The centers of tuberculous granulomas often have characteristic caseation (“cheese-like”) necrosis; organisms may or may not be seen with acid-fast staining. The demonstration of characteristic caseating granulomas on a tissue section in the appropriate clinical and epidemiologic circumstances strongly supports a diagnosis of active tuberculosis, but it is not pathognomonic; culture is required to establish a laboratory diagnosis
The sarcoid granuloma is a focal, chronic inflammatory reaction formed by the accumulation of epithelial cells, monocytes, lymphocytes, macrophages, and fibroblasts. Multinucleated giant cells are frequently found among the epithelioid cells within the granuloma follicle and often have cytoplasmic inclusions, such as asteroid bodies, Schaumann bodies, and birefringent crystalline particles (calcium oxalate and other calcium salts). Most sarcoid granulomas gradually resolve and leave few or no residual manifestations of previous inflammation. Small amounts of central fibrinoid necrosis may be seen, but large amounts of necrosis suggest an alternate diagnosis or necrotizing sarcoid granulomatosis.]
What are the accessory breathing muscles?
- Sternocleidomastoid
- Pectoralis major and minor
- Serratus posterior
- Scalenes (anterior, medius, and posterior)
[Also the Inferior fibers of serratus anterior and latissimus dorsi]
What is the most common type of lung cancer?
Adenocarcinoma
[UpToDate: Adenocarcinoma is the most common type of lung cancer in contemporary series, accounting for approximately one-half of lung cancer cases. The increased incidence of adenocarcinoma is thought to be due to the introduction of low-tar filter cigarettes in the 1960s, although such causality is unproven. The World Health Organization (WHO) classification emphasizes that tissue specimens should be managed not only for pathologic diagnosis, but also to preserve tissue for molecular studies, which may have important treatment implications such as use of targeted therapies for certain subsets of patients. Patients with advanced lung adenocarcinoma and other non-small carcinomas not otherwise specified should have their tumors tested for the presence of a driver mutation (eg, mutated epidermal growth factor receptor, ALK translocation, and increasingly, other mutations).]
What percent of lung carcinoid tumors have metastases at the time of diagnosis?
5%
[Lung carcinoid tumors are uncommon and tend to grow slower than other types of lung cancers. They are made up of special kinds of cells called neuroendocrine cells.]
[UpToDate: Bronchial neuroendocrine (carcinoid) tumors (NETs) are an uncommon group of pulmonary neoplasms that are characterized by neuroendocrine differentiation and relatively indolent clinical behavior.
Like neuroendocrine tumors at other body sites, bronchial NETs are thought to derive from peptide- and amine-producing neuroendocrine cells. NETs can arise at a number of sites throughout the body, including the thymus, lung, gastrointestinal (GI) tract, and ovary. The GI tract is the most frequently involved site, while lung is the second most common.]
This is a neuroendocrine lung tumor that usually occurs centrally
Carcinoid tumor
[UpToDate: Bronchial neuroendocrine (carcinoid) tumors are a rare group of pulmonary neoplasms that are often characterized by indolent clinical behavior. Like other carcinoid tumors, bronchial carcinoids are thought to derive from peptide- and amine-producing neuroendocrine cells. Bronchial neuroendocrine tumors (NETs) can arise at a number of sites throughout the body, including the thymus, lung, gastrointestinal (GI) tract, and ovary. The GI tract is the most frequently involved site for NETs, while lung is the second most common.
Bronchial NETs are characterized by strikingly heterogeneous pathological features and clinical behavior. At one end of the spectrum are typical carcinoid tumors, which are well differentiated, low-grade slowly-growing neoplasms that seldom metastasize to extrathoracic structures. At the other end of the spectrum are the poorly-differentiated and high-grade neuroendocrine carcinomas, as typified by small-cell lung cancer (SCLC), which behaves aggressively, with rapid tumor growth and early distant dissemination. The biologic behavior of atypical carcinoid tumors, which are of intermediate grade and differentiation, is intermediate between typical carcinoid tumors and SCLC. The terms “typical” and “atypical” carcinoid of the lung correspond roughly to the terms “low-grade” and “intermediate-grade,” which are used more commonly in extrathoracic NETs.
Multifocal disease is not uncommon in patients with low-grade bronchial NETs. An extreme example is diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH), a benign condition characterized by diffuse hyperplasia of pulmonary neuroendocrine cells and formation of multiple carcinoid tumorlets.]
What kind of pleural fluid collection has:
- >1,000 WBCs (>50,000 is highly specific)
- pH <7.30
- Pleural fluid protein to serum ratio >0.5
- Pleural fluid LDH to serum ration >0.6?
Empyema
[UpToDate: Pleural fluid LDH levels above 1000 IU/L (with upper limit of normal for serum of 200 IU/L) are characteristically found in empyema, rheumatoid pleurisy, and pleural paragonimiasis, and are sometimes observed with malignancy.
Increased acid production by pleural fluid cells and bacteria (empyema) cause pleural fluid acidosis (pH <7.30).
The total pleural fluid nucleated cell count is virtually never diagnostic. There are, however, some settings in which the count may be helpful. Counts above 50,000/microL are usually found only in complicated parapneumonic effusions, including empyema.]
What tumor invades the apex of the chest wall and results in patients having Horner’s syndrome?
Pancoast tumor
[Horner syndrome results from invasion of the sympathetic chain and is characterized by ptosis, miosis, and anhidrosis, and/or ulnar nerve symptoms.]
How is a diagnosis of a lung hamartoma made?
CT with a repeat CT in 6 months to confirm the diagnosis
[UpToDate: Hamartomas cause approximately 10% of benign nodules found in the lung. They typically present in middle age, grow slowly over years, and are histologically heterogeneous. Cartilage (with scattered calcification), fat, muscle, myxomatous tissue, and fibroblastic tissue may all exist. The characteristic appearance of a hamartoma on a chest radiograph is a SPN with “popcorn” calcification, although this pattern is observed in less than 10% of cases. High-resolution CT scanning of the lesion is particularly useful because it may demonstrate focal areas of fat, or calcification alternating with fat, which are virtually diagnostic of a hamartoma. Less common benign neoplasms such as fibromas, leiomyomas, hemangiomas, amyloidoma, and pneumocytoma do not have characteristic features on imaging.]
What is the treatment for a mediastinal teratoma?
- Resection
- Possible chemotherapy
[UpToDate: Treatment of mature mediastinal teratomas is surgical excision, and this is almost always curative. Resection generally is through a median sternotomy or posterolateral thoracotomy, depending upon the location of the tumor, although thoracoscopic resection is occasionally possible.
Subtotal resection with relief of compressive symptoms is performed if benign teratomas cannot be excised completely without endangering surrounding vital structures. If only subtotal resection is possible, it is not clear that additional treatment with chemotherapy or radiotherapy offers any benefit. Mature teratomas are relatively insensitive to both chemotherapy and radiation therapy (RT).]
Whiteout on chest xray with a midline shift away from the whiteout is most likely due to what?
Effusion (Place chest tube)
What is the most common anterior mediastinal mass in adults?
Thymoma
[UpToDate: The thymus arises from the third pharyngeal pouch at the sixth week of gestation. After the first year of life, the thymus decreases in size and mass until middle age. The relationship of the thymus to other mediastinal structures is shown in the figure. Thymic lesions account for approximately one-half of all anterior mediastinal masses, and can include a range of benign and malignant histologies.
Thymomas account for about 20% of mediastinal neoplasms. Most thymoma patients are between 40 and 60 years of age, and there is a similar incidence in men and women. There are no known risk factors, although there is a strong association with myasthenia gravis and other paraneoplastic syndromes.
Thymomas are associated with a variety of paraneoplastic syndromes. The most common is myasthenia gravis, which occurs in approximately 30% of patients with thymoma. Furthermore, some patients who are diagnosed with myasthenia gravis will be found to have a thymic mass on imaging. Evaluating patients with thymoma for the presence of myasthenia prior to pursuing treatment can be very important, because of the potential impact on a patient’s response to general anesthesia.
Patients with a thymic mass who have not been evaluated for myasthenia gravis should be tested for anti-acetylcholine receptor antibodies. Patients who test positive for these antibodies should be evaluated prior to undergoing anesthesia to determine if they have myasthenia gravis.]
What are the two preferred chemotherapy agents for stage II or higher non-small cell lung cancer?
Carboplatin and Taxol
[UpToDate: Patients with advanced NSCLC should have tumor assessed for the presence of a somatic driver mutation (eg, EGFR, ALK fusion oncogene). The choice of initial therapy (chemotherapy versus molecularly targeted agents) is guided by this information. This information is also useful in guiding subsequent therapy.
For patients whose tumor does not contain a driver mutation, we recommend combination therapy that incorporates a platinum (cisplatin, carboplatin) based doublet (Grade 1A). For patients with nonsquamous NSCLC, we suggest that initial treatment also include bevacizumab (Grade 2B). For patients in whom the increased toxicity or cost of bevacizumab is a significant issue, chemotherapy alone is a reasonable alternative.
- Combinations using cisplatin have a slightly higher response rate but inconsistent survival benefits compared with carboplatin-based regimens. For the majority of patients who will receive a chemotherapy doublet, we suggest using a carboplatin-based regimen (Grade 2B). However, a cisplatin-based regimen is a reasonable alternative in appropriate patients.
- We recommend that the duration of treatment with the initial doublet chemotherapy regimen be limited to four to six cycles (Grade 1A).
For patients with an objective response following the initial cycles of platinum based chemotherapy, we suggest that patients continue on maintenance therapy (Grade 2B). Options included single agent chemotherapy, bevacizumab, or targeted therapy with an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. An alternative approach might be close observation with initiation of second-line therapy at the earliest sign of progression for selected patients who are well informed about the risks and benefits of such approach.
For patients whose initial regimen included bevacizumab in addition to a chemotherapy doublet, the bevacizumab is generally continued in the absence of toxicity until there is evidence of progressive disease, without the addition of cytotoxic chemotherapy.
- For patients whose initial regimen did not include bevacizumab, and whose tumors do not contain a driver mutation, we suggest maintenance chemotherapy with single agent chemotherapy rather than an EGFR tyrosine kinase inhibitor (Grade 2C). For patients with non-squamous NSCLC who are treated with maintenance chemotherapy, we suggest pemetrexed (Grade 2C). Docetaxel and gemcitabine are appropriate alternatives, and the EGFR tyrosine kinase inhibitor erlotinib may also be an alternative in selected patients.
- For patients with squamous cell NSCLC who are treated with maintenance chemotherapy, we suggest either docetaxel or gemcitabine, rather than pemetrexed (Grade 2C).]
Arterio-venous malformations (AVMs) are connections between the pulmonary arteries and pulmonary veins and can be seen in association with which condition?
Osler-Weber-Rendu disease
[UpToDate: Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome), an autosomal dominant vascular disorder, has a variety of clinical manifestations. Among the most common are epistaxis, gastrointestinal bleeding, and iron deficiency anemia, along with characteristic mucocutaneous telangiectasia. In addition, arteriovenous malformations (AVMs) commonly occur in the pulmonary, hepatic, and cerebral circulations, demanding knowledge of the risks and benefits of screening and treatment of patients with these complications.]
When is surgery indicated for treatment of spontaneous pneumothorax?
- Recurrence
- If air leak lasts greater than 7 days
- Non-reexpansion of the lung
- High-risk profession (pilot, diver, mountain climber)
- Patient lives in a remote area
[UpToDate: We suggest a preventive intervention for patients experiencing their first PSP if they are undergoing VATS or tube thoracostomy as part of their initial management, or have a vocation in which recurrence of the pneumothorax is dangerous to the patient or others (eg, airplane pilot or deep sea diver). Otherwise, we prefer to forego preventive interventions until a patient experiences recurrent PSP.
Once it has been determined that a preventive procedure is required, we recommend VATS with pleurodesis, rather than tube thoracostomy with chemical pleurodesis (Grade 1B). This procedure reduces the recurrence rate to less than 5%.
For patients who are not operative candidates or who refuse VATS, we recommend tube thoracostomy with chemical pleurodesis, rather than tube thoracostomy drainage alone, once it has been determined that a preventive intervention is indicated (Grade 1A). This procedure reduces the recurrence rate to less than 25%.]
Which type(s) of bronchial adenoma is slow growing, can have 10-year survival with incomplete resection, and is treated with resection (XRT can provide good palliation if unresectable)?
Adenoid cystic adenoma
[UpToDate: Adenoid cystic carcinoma (ACC) was previously considered to be the most common form of malignant minor salivary gland tumor. Many of these cases subsequently have been reclassified as polymorphous low-grade adenocarcinoma (PLGA). ACC arises in both major and minor salivary glands. The tumor is locally aggressive, with recurrences often arising after many years.
Three basic growth patterns are commonly seen: tubular, cribriform, and solid. These patterns are often mixed. The biologic aggressiveness of ACC correlates with the amount of the solid component within the tumor. The solid areas generally contain cells with larger, more pleomorphic nuclei, increased mitotic activity, and often, foci of necrosis. A grading scheme attempts to integrate the varied histologic components: grade 1 tumors are composed entirely of tubules or cribriform areas, while the presence of a solid component defines higher-grade tumors. A 30% solid component serves as the breakpoint between grade 2 and 3 tumors.
In a study of 129 cases, clinical stage, solid growth pattern, and p53 expression were found by multivariate analysis to be the most important prognostic features in head and neck ACC. Increased proliferative activity has also been reported as an adverse prognostic factor. ACC frequently demonstrates bone and perineural invasion. As with other tumors that commonly invade perineural spaces, neural cell adhesion molecule (NCAM), nerve growth factor (NGF) and its receptor, and TrkA are commonly expressed in adenoid cystic carcinoma, and may provide the molecular basis underlying its behavior.
Surgical resection is the treatment of choice for malignant tracheal tumors whenever possible, given retrospective data suggesting improved disease outcomes and acceptable postoperative morbidity. Because of the lack of suitable replacement material, the suggested maximum resected length of trachea is 5 cm. Decisions on resectability are based on imaging studies and the expertise of the surgical team. Studies have suggested that between 50% and 70% of patients have resectable disease at diagnosis.
The superiority of surgery, with or without radiation, to radiation alone was suggested in a Netherlands database series in which 34 patients underwent surgical resection (24 of whom also received radiation) and 156 patients were treated with RT alone. The five-year survival among patients who underwent surgical resection was 53% versus 11% among those receiving RT alone. A retrospective analysis of adenoid cystic carcinoma (ACC) of the head and neck similarly noted that radiotherapy combined with surgery resulted in better local control and survival than treatment with radiation alone. A limitation in the interpretation of these retrospective studies is that the group of patients treated nonsurgically included those with unresectable disease and therefore a worse prognosis, which biases the results toward surgical treatment.]
Which test is needed for centrally located lung tumors?
Bronchoscopy
[to check for airway invasion]
[UpToDate: Bronchoscopy with endobronchial ultrasound (EBUS)-directed biopsy has emerged as the most common modality used for diagnosis and staging of suspected NSCLC due to its high diagnostic accuracy for accessing central primary tumors and most mediastinal lymph nodes. Furthermore, EBUS-directed biopsy in patients with mediastinal adenopathy on computed tomography (CT) scan may be performed quickly and reduce the time to establishing of treatment decisions. If initial tissue sampling provides inconclusive results or is insufficient for essential immunohistochemical or molecular characterization, a second biopsy procedure is required. The selection of a second biopsy procedure should favor modalities with a higher diagnostic yield (eg, surgical sampling). The selection of modality and procedures used for tissue biopsy of NSCLC are discussed separately. Although genetic and molecular microarray techniques of both tissue and peripheral blood have been studied as potential diagnostic tools designed to enhance the sensitivity of bronchoscopy for the diagnosis of lung cancer, further study is required before they can be recommended for routine use.]
Injury at what level of the thorax results in a right-sided chylothorax?
Below T5-T6
[UpToDate: Generally, the thoracic duct ascends from the cisterna chyli (sac at the lower end of the thoracic duct into which the intestinal and two lumbar lymphatic trunks drain), which lies just anterior to the first or second lumbar vertebra, and passes through the aortic hiatus of the diaphragm to enter the posterior mediastinum, although wide anatomic variation exists. The thoracic duct continues cephalad in a rightward position between the aorta and azygos vein until it reaches the approximate level of the fifth thoracic vertebra, where it crosses over the vertebral column behind the esophagus and continues in the left posterior mediastinum. The thoracic duct in this region is 2 to 3 mm in diameter and passes behind the aortic arch adjacent to the left side of the esophagus and behind the left subclavian artery. It then arches over the subclavian artery in the anterolateral superior mediastinum, descending to empty into the venous circulation in the region of the left jugular and subclavian veins.
In some patients, two thoracic ducts exist within the mediastinum, and occasionally a single thoracic duct may empty into right-sided venous structures.
The anatomy of the thoracic duct determines the location of the effusion seen with duct injury or obstruction. Because the thoracic duct crosses the mediastinum at the fifth thoracic vertebral body, lymphatic injury or obstruction below this level generally results in a right–sided pleural effusion. In contrast, disease above this level usually leads to a left-sided effusion.]
Lung adenocarcinoma usually occurs where?
Peripherally
[UpToDate: Adenocarcinoma is the most common type of lung cancer in contemporary series, accounting for approximately one-half of lung cancer cases. The increased incidence of adenocarcinoma is thought to be due to the introduction of low-tar filter cigarettes in the 1960s, although such causality is unproven. The World Health Organization (WHO) classification emphasizes that tissue specimens should be managed not only for pathologic diagnosis, but also to preserve tissue for molecular studies, which may have important treatment implications such as use of targeted therapies for certain subsets of patients. Patients with advanced lung adenocarcinoma and other non-small carcinomas not otherwise specified should have their tumors tested for the presence of a driver mutation (eg, mutated epidermal growth factor receptor, ALK translocation, and increasingly, other mutations).]
Do lung hamartomas require resection?
No
[UpToDate: Hamartomas cause approximately 10% of benign nodules found in the lung. They typically present in middle age, grow slowly over years, and are histologically heterogeneous. Cartilage (with scattered calcification), fat, muscle, myxomatous tissue, and fibroblastic tissue may all exist. The characteristic appearance of a hamartoma on a chest radiograph is a SPN with “popcorn” calcification, although this pattern is observed in less than 10% of cases. High-resolution CT scanning of the lesion is particularly useful because it may demonstrate focal areas of fat, or calcification alternating with fat, which are virtually diagnostic of a hamartoma. Less common benign neoplasms such as fibromas, leiomyomas, hemangiomas, amyloidoma, and pneumocytoma do not have characteristic features on imaging.]
Recurrent pleural effusions can be treated with what?
Mechanical pleurodesis (Talc pleurodesis for malignant pleural effusions)
[UpToDate: Patients who have symptoms due to recurrent or persistent pleural effusion despite therapy directed at the underlying cause are candidates for additional therapies. Asymptomatic patients do not require additional interventions.
Prior to proceeding with more invasive therapy, the underlying cause of the NMPE should be reconfirmed (with thoracoscopic pleural biopsy) to ensure that primary treatment has been appropriate; infectious causes, hepatic hydrothorax, and trapped lung should also be excluded.
We suggest talc pleurodesis or implanted pleural catheters and intermittent drainage for patients who have symptoms due to refractory nonmalignant pleural effusions (Grade 2C).
We suggest talc pleurodesis for patients who have symptoms due to refractory nonmalignant pleural effusions and in whom repeat therapeutic thoracenteses have become burdensome (Grade 2C). The greatest pleurodesis experience is with talc; however, this choice is controversial due to concerns about immediate and long-term side effects of talc. Pleurodesis, however, should only be performed in this setting after a multi-disciplinary discussion of the risks, benefits, and alternatives.]
What is the treatment for lung carcinoid tumors?
Resection
[Treat like cancer. Outcome closely linked to histology]
[UpToDate: For patients with either a typical or atypical resectable bronchial NET whose medical condition and pulmonary reserve will tolerate it, we recommend surgical resection and mediastinal lymph node sampling or dissection (Grade 1B). The presence of mediastinal lymph node metastases does not preclude cure.
For most patients, endobronchial resection is a suboptimal method of definitive treatment, and we suggest not pursuing this approach over definitive surgical resection (Grade 2C). Endobronchial laser resection is best reserved for palliative treatment of patients with central airway occlusion who are poor surgical candidates (eg, elderly, debilitated).
Although some disagree, we suggest not administering postoperative adjuvant therapy for most resected bronchial NETs even in the setting of positive lymph nodes (Grade 2C). Adjuvant platinum-based chemotherapy with or without radiation therapy (RT) is a reasonable option for patients with histologically aggressive-appearing stage III atypical bronchial NETs (ie, relatively high mitotic rate, extensive necrosis, etc.), although there is only limited evidence to support this.
RT is a reasonable option for atypical bronchial NETs if gross residual disease remains after surgery, although whether this improves outcomes is unproven.]
What is the most common early complication after tracheal surgery?
Laryngeal edema
[UpToDate: Evidence suggests that laryngeal inflammation and edema are detected after extubation in more than half of patients, although not every case is associated with significant symptomatology.
Following extubation, most patients complain of mild to moderate symptoms including sore throat, dysphonia, and dysphagia thought to be due to laryngeal inflammation from the ETT.
More severe symptoms include stridor (sometimes requiring reintubation), which may be due to coexistent impairment in vocal cord mobility. As an example, one prospective study, clinically significant laryngeal edema occurred in approximately 5-13% of patients and required reintubation in approximately 1%.
Laryngeal edema may be suspected prior to extubation or following extubation failure and may be supported by the presence of a negative cuff leak test.]
When is surgery indicated in a clotted hemothorax?
- Involvement of greater than 25% of lung
- Air-fluid levels are present
- Signs of infection
[surgery in 1st week to avoid peel]
[UpToDate: Hemothorax is treated with tube thoracostomy using a large (minimum 36 French) chest tube. Immediate bloody drainage of ≥20 mL/kg (approximately 1500 mL) is generally considered an indication for surgical thoracotomy. Shock and persistent, substantial bleeding (generally >3 mL/kg/hour) are additional indications. Vital signs, fluid resuscitation requirements, and concomitant injuries are considered when determining the need for thoracotomy.
In general, a pneumohemothorax is treated with drainage by tube thoracostomy. Small, clinically insignificant collections may be treated with needle aspiration or drainage, at the discretion of the trauma surgeon.]
Which pulmonary nodes are assessed by mediastinoscopy?
- Ipsilateral (N2)
- Contralateral (N3)
- Mediastinal nodes
[if mediastinal nodes are positive, the tumor is unresectable.]
[UpToDate: SCM can easily access pretracheal (1, 3), paratracheal (2R, 2L, 4R, 4L), anterior subcarinal (7) and occasionally hilar (10) nodes. It is not able to sample subaortic (5) or para-aortic (6), inferior (8, 9), posterior subcarinal (7), or lobar/interlobar (11 to 14) stations. Use of the video mediastinoscope can extend access to the posterior subcarinal nodes (station 7). SCM is best used to sample lymph nodes in these selected stations, particularly when other staging modalities have failed or are not available.]
What are the different TNM stages of lung cancer?
- Stage I: T1-2, N0, M0
- Stage IIa: T1, N1, M0
- Stage IIb: T2, N1, M0 or T3, N0, M0
- Stage IIIa: T1-3, N2, M0 or T3, N1, M0
- Stage IIIb: any T4 or N3 Stage IV: M1
Which stages of lung cancer are resectable?
Stage I, stage II, and possibly stage IIIa (T3,N1,M0)
[UpToDate: A patient with lung cancer may be “resectable” by virtue of having a surgically removable NSCLC, but may not be “operable” due to poor pulmonary function or comorbidities. Advances in surgical technique, the role of limited resection, and postoperative care may provide the opportunity for surgical resection in patients who previously might not have been considered candidates for aggressive treatment.
Patients with stage I or II NSCLC should be treated with complete surgical resection whenever possible. Postoperative adjuvant chemotherapy improves survival in patients with pathologic stage II disease and may have a role for patients with stage IB disease.
Patients with stage I or II disease who are not candidates for surgical resection or who refuse surgery may be candidates for nonsurgical local therapy. Radiation may be applied by stereotactic techniques or conventional methods. Radiofrequency ablation (RFA) and cryoablation are alternatives to radiation. Photodynamic therapy may also be useful as a primary treatment modality in carefully selected patients with superficial airway lesions.
For patients with pathologically proven stage III disease prior to definitive therapy, a combined modality approach using concurrent chemoradiotherapy is generally preferred. The role of surgery following chemoradiotherapy is an area of active investigation. Surgery may also retain a role for carefully selected patients with T3 or T4 lesions and negative mediastinal lymph nodes.]
How can one go about assessing enlarged Aorto-pulmonary (AP) window nodes?
Chamberlain procedure (anterior thoracotomy or parasternal mediastinotomy)
[Go through the left 2nd rib cartilage.]
[UpToDate: A left anterior mediastinotomy (Chamberlain procedure) is a surgical procedure that requires general anesthesia. The incision is made over the left second or third intercostal space to access lymph nodes in station 5. Due to lymphatic drainage patterns, cancers of the left upper lobe preferentially drain to this regions. However, this region are traditionally difficult to access and cannot be reached by minimally invasive techniques or by standard cervical mediastinoscopy.
A left anterior mediastinotomy is the traditional surgical procedure used to stage left-sided cancer when suspected nodes are located in station 5. It has the added advantage of accessing left upper lobe tumors for concurrent resection, if there is no evidence of nodal or distant disease.
Because it is often the only option when suspicious lymph nodes are identified in this region, there is a paucity of data regarding its diagnostic accuracy. Nonetheless, one meta-analysis of four small studies reported a sensitivity and negative predictive value of 71% and 91% respectively. No studies have directly compared its performance to ECM, VATS), or to endoscopic ultrasound-guided fine needle aspiration which can occasionally reach this region.]
What kind of pneumothorax occurs in temporal relation to menstruation and is caused by endometrial implants in the visceral lung pleura?
Catamenial pneumothorax
[UpToDate: Thoracic endometriosis should always be suspected in young women with catamenial or non-catamenial pneumothorax or hemothorax, who have a history of prior uterine surgical procedures or pelvic endometriosis (present in 65% to 84%). In such patients, the diagnostic and therapeutic approach is often performed simultaneously (eg, thorascopic biopsy, blebectomy, and pleurodesis).]
What is the treatment for the second phase of empyema (fibro-proliferative phase - 2nd week)?
- Chest tube
- Antibiotics
- Possible VATS deloculation
[UpToDate: In patients with a parapneumonic effusion or an empyema, an empiric, broad spectrum antibiotic that includes coverage for anaerobic organisms should be initiated promptly, because empyemas often harbor multiple species of bacteria, particularly anaerobes.
In patients with an uncomplicated parapneumonic effusion, one that is small to moderate in size, free flowing, and has a pH of 7.20 or greater, we recommend observation rather than placement of a chest tube for drainage (Grade 1B).
In patients with a large, loculated, or complicated parapneumonic effusion, we recommend prompt drainage of any remaining pleural fluid rather than observation (Grade 1B). For further drainage of the pleural space, we suggest tube thoracostomy rather than a more invasive procedure (eg, thoracoscopy, decortication) (Grade 2C). Computed tomography (CT) or ultrasound-guided placement of multiple tubes may be needed when pleural loculations prevent adequate drainage by a single tube. Video-assisted thoracoscopic surgery (VATS) with debridement may be preferred in patients with multiple loculations and a thick pleural peel.
When tube thoracostomy is used for initial drainage of an empyema, a chest CT scan should be obtained within 24 hours after chest tube placement to document appropriate placement of the tube and assess drainage. For patients with ongoing signs of infection (fever, leukocytosis, anorexia) or those who do not have good drainage of empyema fluid from a well-placed chest tube, we suggest intrapleural administration of a combination of tissue plasminogen activator (TPA) 10 mg and deoxyribonuclease (DNase) 5 mg, twice daily for three days rather than no intrapleural therapy or either agent alone (Grade 2B).
Continued signs of infection together with failure of adequate pleural drainage should prompt thoracoscopy or thoracotomy to lyse adhesions, fully drain the pleural space, and optimize chest tube placement. The choice between thoracoscopic debridement and decortication depends on several factors; those favoring decortication include more adhesions, greater visceral pleural thickness, and larger empyema cavity size.]
Do all thymomas require resection?
Yes
[UpToDate: Surgical management should include a complete resection of the thymus. The current standard of care is an open surgical approach via a median sternotomy. A minimally invasive (thoracoscopic or robotic) approach is not recommended except in the context of specialized centers with experience in these techniques.
The ability to completely resect a thymoma or thymic carcinoma is determined by the extent of tumor, including the degree of invasion and/or adhesion of the tumor to contiguous structures. The likelihood of long-term survival depends upon the completeness of surgical resection. Resection of the pericardium as well as accompanying lung parenchyma is sometimes required to achieve a complete resection with histologically negative margins.
An inflammatory fibrous reaction can mimic tumor invasion, and tumor may be adherent to adjacent structures without being invasive. In such cases, the surgeon should identify the site of adhesion on the resection specimen, so the pathologist can take careful sections from that area.
Extension of a tumor along one or both phrenic nerves can create a dilemma since division of the phrenic nerves may impair respiratory function. Preoperative pulmonary function studies should be obtained in all patients so that the extent of respiratory compromise following division of the phrenic nerve can be estimated.
Resection of one involved phrenic nerve, followed by dissection of the other nerve away from the surrounding tumor, is recommended if possible to reduce postoperative respiratory disability. However, if the patient has myasthenia gravis, resection of even one phrenic nerve may lead to significant respiratory problems.]
What is the treatment of post-intubation stenosis?
- Serial dilatation
- Bronchoscopic resection
- Laser ablation (if minor)
- Tracheal resection with end-to-end anastamosis if severe or if it keeps recurring
[UpToDate: Stenosis of the larynx and/or trachea is a late complication of ETT placement taking weeks to months to develop after the initial intubation. The risk of developing stenosis is increased in those with prolonged intubation >7 days, and is rare in those intubated for short periods (eg, <3 days). The incidence is unknown but reports range from 1-21%.
- Glottic (laryngeal) stenosis is thought to be due to pressure from the ETT itself, resulting in local tissue ischemia, inflammation, necrosis, and scarring. In support of this mechanism, inflammatory changes are seen in this region in as few as two to five days after intubation and most cases are located in the posterior glottis and interarytenoid regions, where the ETT rests.
- Tracheal stenosis is caused by high ETT cuff pressure. When the ETT cuff pressure exceeds the mean capillary pressure in the tracheal mucosa (approximately 20 cm H2O), obstruction of capillary blood flow causes ischemia, inflammation, and erosion of the mucosa. This leads to necrosis, destruction of the tracheal architecture, and scarring.
Patients who are extubated may develop subacute or progressive dyspnea and/or or stridor while those who remain intubated (usually tracheostomized may present with failure to wean from mechanical ventilation. Tracheal stenosis usually becomes symptomatic within five weeks after extubation, sometimes longer (eg, months), and symptoms may become progressive over time. Stenosis may remain occult in a sedentary or deconditioned individual who is physically inactive. Pulmonary function testing may demonstrate upper airway obstruction. If the patient remains intubated, a negative cuff leak test may support the diagnosis. Definitive diagnosis requires bronchoscopy or laryngoscopy, although emerging data suggests that spiral computed tomography (CT) with virtual bronchoscopy may be equally effective.
Tracheal stenosis may require endoscopic stenting, balloon dilations, laser resection, or an alternative endoscopic intervention. Rates of success with endoscopic procedures are variable. Mitomycin C, an antineoplastic agent has been used anecdotally to prevent tracheal restenosis, although randomized studies are lacking. Surgical resection is usually reserved for those with symptoms from extensive stenosis or those who fail endoscopic procedures. In contrast, stenotic lesions that involve the larynx are typically less amenable to endoscopic procedures and subspecialty consultation is advised.
More rarely, an obstructive fibrinous tracheal pseudomembrane may cause tracheal obstruction and be responsible for extubation failure. In such cases, fiberoptic bronchoscopy reveals a thick, circular, rubber-like membrane adhering to the tracheal wall at the site of the endotracheal tube cuff. Rigid bronchoscopy is usually required for the removal of the pseudomembrane.]
What is the single best test for M status of lung cancer?
PET scan
What is the treatment for a pericardial cyst?
Leave it alone (benign)
[UpToDate: Pericardial cysts occur with an incidence of 1 in 100,000 patients. Seventy percent arise in the right cardiophrenic angle. Symptoms can include shortness of breath, right heart failure secondary to compression, infection, and bleeding.
Asymptomatic pericardial cysts can be observed, but resection may be needed if the diagnosis is not completely established by imaging. Simple drainage is generally not recommended because these cysts typically recur without complete resection.]
Tracheo-innominate artery fistula can occur after what procedure?
Tracheostomy
[Can cause rapid exsanguination]
[UpToDate: Massive hemorrhage due to a tracheoarterial fistula is the most devastating complication. In several studies, the incidence of a tracheoarterial fistula was less than 1% with both short-term and long-term tracheostomies.]
Which lung cancer can look like pneumonia, grows along alveolar walls, and is multifocal?
Bronchoalveolar cancer
[UpToDate: Bronchioloalveolar carcinoma (BAC) can have a highly variable clinical presentation, which ranges from a small solitary nodule or limited number of nodules, to more extensive miliary disease, or diffuse parenchymal infiltrates that are similar in appearance to a bacterial pneumonia.
When disease is more extensive, BAC patients can present with lobar consolidation that resembles bacterial pneumonia. CT scans typically show air bronchograms or even the CT angiogram sign, which is observed when the massive accumulation of mucus in the airspaces delineates the nearby vasculature. By the new classification, these are most commonly mucinous adenocarcinomas. The diagnosis of BAC may not be considered until the clinical symptoms and radiographic abnormalities fail to respond to antibacterial treatment. Unfortunately, this so-called “pneumonic” form of BAC has been associated with a particularly poor prognosis.]
What types of mediastinal masses are located in the posterior mediastinum?
- Enteric cysts
- Neurogenic tumors
- Lymphoma
[UpToDate: Neurogenic tumors represent more than 60% of posterior mediastinal masses. These lesions are classified based upon their neural cell of origin.
Schwannomas and neurofibromas are benign lesions that arise from the intercostals nerve sheath and make up 90% of adult neurogenic tumors.
Neuroblastomas and ganglioneuroblastomas are malignant tumors that occur most commonly in children and originate from the sympathetic ganglia.
Ganglioneuromas are benign lesions that arise from the sympathetic ganglia, and are most common in young adults. Lesions that arise from para-ganglionic cells include pheochromocytomas and paragangliomas.
Some neurogenic tumors are “dumbbell shaped” and arise near intervertebral foramen, and have a posterior mediastinal and intraspinal component. Resection usually requires a combined approach with neurosurgery and thoracic surgery.]
What percent of symptomatic mediastinal masses are malignant?
50%
[UpToDate: Patients with mediastinal masses can present in a variety of ways. A mediastinal mass is often an incidental diagnosis when patients undergo an evaluation for an unrelated condition or symptom. In some cases, patients present with complaints secondary to local mass effect on adjacent structures, such as respiratory symptoms due to airway compression or swelling due to compression of vascular structures. Other patients develop systemic symptoms that result from the mediastinal mass, which is discovered on subsequent work-up.
Benign or malignant mediastinal masses can develop from structures that normally are in the mediastinum or that pass through the mediastinum during development, as well as from metastases of malignancies that arise elsewhere in the body. A combination of clinical factors and imaging features often narrow the differential diagnosis when a mediastinal mass is detected. In some instances, the clinical and imaging features can be enough to guide therapy, which often includes surgical resection that provides a definitive diagnosis. Blood tumor markers can sometimes also support a specific diagnosis. In other cases, obtaining tissue via biopsy can be necessary to confirm a clinical suspicion prior to proceeding with therapy.]
What is the most common malignant chest wall tumor?
Chondrosarcoma
[UpToDate: Chondrosarcoma is the most common malignant chest wall tumor. It is located on the anterior chest wall (costochondral arches or sternum) and can arise from a degenerated chondroma. Presentation is usually as a slowly growing painful mass with a hard, fixed chest wall lesion; 10% of patients have lung metastases at presentation. Wide excision is recommended because of an increased risk of recurrence and metastasis following incomplete resection. Radiation therapy is recommended for unresectable or incompletely resected tumors. Five-year survival rates are between 70% and 90%.]
What is the treatment for laryngeal edema following tracheal surgery?
- Reintubation
- Racemic epinephrine
- Steroids
[UpToDate: We believe that the risk for post-extubation stridor is more important than the number of doses administered when deciding whether giving glucocorticoids prior to extubation may be beneficial. This is supported by a trial that randomly assigned 71 patients with a cuff leak of less than 24% of the tidal volume administered by the ventilator to receive either a saline placebo or a single dose of 40 mg of methylprednisolone four hours prior to extubation. The group that received the methylprednisolone had significantly decreased rates of post-extubation stridor (16% vs 39%) and reintubation (8% vs 30%) than the group that received the placebo.
We suggest that patients whose extubation is delayed due to a reduced cuff leak receive a short course of glucocorticoid therapy before extubation. Methylprednisolone (20 mg) administered every four hours for a total of four doses prior to extubation is an acceptable regimen. Alternatively, a single dose of 40 mg of methylprednisolone administered four hours prior to extubation may be used.
We limit glucocorticoid therapy to those patients who have a reduced cuff leak, since the overall incidence of postextubation laryngeal edema requiring reintubation is low (<5%). We believe this approach focuses therapy on those who are most likely to benefit and avoids unnecessarily prolonging mechanical ventilation for glucocorticoid therapy.]
What measure can be taken to avoid a tracheo-innominate artery fistula when performing a tracheostomy?
Keep tracheostomy above 3rd tracheal ring
[UpToDate: Massive hemorrhage due to a tracheoarterial fistula is the most devastating complication. Tracheoarterial fistula (most often a tracheoinnominate artery fistula) was more common in the past from low-positioned tracheostomy tubes and is now rarely encountered with several studies reporting an incidence of less than 1% with both short-term and long-term tracheostomies.
The development of a tracheoarterial fistula is a life-threatening complication with a reported survival of 14%. Tracheoarterial fistulas are due to erosion from the tube tip or cuff into the anterior wall of the trachea resulting in a fistulous communication with the innominate artery as it passes anteriorly across the trachea. Patients may develop a “sentinel” bleed followed by massive hemoptysis. Diagnosis is dependent upon a high index of suspicion and when suspected, immediate action should be undertaken to stop the bleeding since diagnostic modalities such as angiography or bronchoscopy may lead to delay and death.]
What percent of patients with myasthenia gravis have a thymoma?
10%
[50% of patients with thymomas have myasthenia gravis.]
[UpToDate: Myasthenia gravis is an autoimmune disorder caused by interference with acetylcholine receptors of voluntary muscle at the neuromuscular junction. Common symptoms include diplopia, ptosis, dysphagia, weakness, and fatigue.
Up to one-half of patients with thymoma have symptoms consistent with myasthenia gravis. Myasthenia gravis is common with all types of thymoma, but is rare in thymic carcinoma. Men and women are equally affected.
Patients with thymoma and myasthenia gravis usually present with less advanced disease than those without myasthenia gravis, possibly because neuromuscular symptoms may lead to an earlier diagnosis. In patients with thymoma and myasthenia gravis, thymectomy usually results in an attenuation of the severity of myasthenia gravis, although some symptoms persist in most patients.
Patients who have detectable antibodies to the acetylcholine receptor (AChR) or to the muscle-specific receptor tyrosine kinase (MuSK) are considered to have seropositive myasthenia gravis, while those lacking both AChR and MuSK antibodies on standard assays are considered to have seronegative myasthenia. About half of patients with purely ocular myasthenia are seropositive, compared with approximately 90% of those with generalized disease. Another important consideration is that about 10-15% of patients with myasthenia gravis have an underlying thymoma.]
Which cell type is responsible for surfactant production in the lungs?
Type 2 pneumocytes
What is the 5-year survival rate of lung cancer following resection for cure?
30%
[UpToDate: The most important prognostic factor in patients with SCLC is the extent of disease (stage) at presentation. For patients with limited stage disease, median survivals range from 15-20 months, and the reported five-year survival rate is 10-13%. In contrast, for patients with extended stage disease, the median survival is 8-13 months, and the five-year survival rate is 1-2%.]
[National Cancer Institute’s SEER database:
NSCLC - This data is based on people who were diagnosed with NSCLC between 1998 and 2000. Although they are based on people diagnosed several years ago, they are the most recent rates published for the current AJCC staging system.
Stage IA NSCLC is about 49%
Stage IB NSCLC is about 45%.
Stage IIA NSCLC is about 30%
Stage IIB NSCLC is about 31%
Stage IIIA NSCLC is about 14%
Stage IIIB NSCLC is about 5%
Stage IV NSCLC is about 1%
SCLC - This data is based on people who were diagnosed with SCLC between 1988 and 2001. These survival rates are based on the TNM staging system in use at the time, which has since been modified slightly for the latest version. Because of this, the survival numbers may be slightly different for the latest staging system. 5-year relative survival rate:
Stage I SCLC is about 31%
Stage II SCLC is about 19%
Stage III SCLC is about 8%
Stage IV SCLC is about 2%]
What percent of lung coin lesions are malignant?
- Overall: 10%
- Age less than 50: <5% malignant
- Age greater than 50: >50% malignant
[UpToDate: Clinical features associated with an increased probability of malignancy include advanced patient age and underlying risk factors. However, young age and the absence of risk factors do not preclude a diagnosis of malignancy.
The probability of malignancy rises with increasing patient age. One study reported a higher frequency of malignant nodules in patients >50 years of age compared with patients
- 35 to 39 years: 3%
- 40 to 49 years: 15%
- 50 to 59: 43%
- ≥60 years: >50%
Risk factors – The probability of malignancy is always higher when a nodule occurs in a patient with a history of smoking, especially current smokers, because of the strong association between cigarette smoking and lung cancer. Other risk factors for lung cancer including family history, female sex, emphysema, prior malignancy, and asbestos exposure should also be considered when evaluating a patient with a nodule.]
What vessel runs along the right side of the thorax, crosses the midline at T4-5, and dumps into the left subclavian vein at the junction with the internal jugular vein?
Thoracic duct
What percent of patients with thymomas have myasthenia gravis?
50%
[10% of patients with myasthenia gravis have a thymoma.]
[UpToDate: Myasthenia gravis is an autoimmune disorder caused by interference with acetylcholine receptors of voluntary muscle at the neuromuscular junction. Common symptoms include diplopia, ptosis, dysphagia, weakness, and fatigue.
Up to one-half of patients with thymoma have symptoms consistent with myasthenia gravis. Myasthenia gravis is common with all types of thymoma, but is rare in thymic carcinoma. Men and women are equally affected.
Patients with thymoma and myasthenia gravis usually present with less advanced disease than those without myasthenia gravis, possibly because neuromuscular symptoms may lead to an earlier diagnosis. In patients with thymoma and myasthenia gravis, thymectomy usually results in an attenuation of the severity of myasthenia gravis, although some symptoms persist in most patients.
Patients who have detectable antibodies to the acetylcholine receptor (AChR) or to the muscle-specific receptor tyrosine kinase (MuSK) are considered to have seropositive myasthenia gravis, while those lacking both AChR and MuSK antibodies on standard assays are considered to have seronegative myasthenia. About half of patients with purely ocular myasthenia are seropositive, compared with approximately 90% of those with generalized disease. Another important consideration is that about 10-15% of patients with myasthenia gravis have an underlying thymoma.]
Which type(s) of bronchial adenoma(s) grow slowly and do not metastasize?
- Mucoepidermoid adenomas
- Mucous gland adenomas
[Treatment is resection.]
[UpToDate: Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. It consists of a mixture of mucin-producing columnar cells, epidermoid (squamous) cells, and polygonal intermediate cells.
While tumor stage is the most important prognostic feature for mucoepidermoid carcinoma, histologic grading has prognostic significance. Low-grade lesions are typically cystic; higher grade lesions become progressively more solid in growth and more difficult to classify correctly.
The WHO system assigns points to individual histologic features, which contribute to a final score. The Armed Forces Institute of Pathology system separates patients into three groups; low-grade tumors have scores of 0-4 points, intermediate-grade tumors 5-6 points, and high-grade mucoepidermoid carcinoma ≥7 points. In one study, there were no locoregional recurrences or distant metastases among patients with low-grade MEC after at least three years of follow-up. In contrast, 45% of patients with high-grade and 67% with intermediate-grade MEC experienced a recurrence or metastases.
In addition to tumor grade, age greater than 40 years, tumor fixation, and T and N stages were individually found to be independent prognostic features. Most reports show that mucoepidermoid carcinomas arising in the submandibular gland tend to behave aggressively, regardless of grade. In contrast, mucoepidermoid carcinoma arising in the pediatric age group tends to have a favorable prognosis.
A translocation involving (11;19)(q21;p13), which produces a unique fusion product, MECT1-MAML2, occurs commonly in mucoepidermoid carcinoma and may be prognostically favorable. Epidermal growth factor receptor (EGFR) is overexpressed in about two-thirds of cases, in contrast to human epidermal growth factor receptor 2 (HER2), which is expressed in less than 5%. Herceptin, a monoclonal antibody that targets HER2 overexpressing cells, appears to have low activity, even among HER2+ cases of salivary gland tumor.]
What percent of patients with thymomas are symptomatic?
50%
[UpToDate: Thymomas and thymic carcinomas typically present in one of three major ways:
- As an incidental finding identified on imaging in an asymptomatic patient.
- Because of local (thoracic) symptoms
- Due to symptoms from a paraneoplastic syndrome.]
Arterio-venous malformations (AVMs) are connections between the pulmonary arteries and pulmonary veins and usually occur where in the lungs?
Lower lobes
[UpToDate: Pulmonary arteriovenous malformations (AVMs) are abnormal connections between pulmonary arteries and pulmonary veins. They allow blood to bypass the pulmonary capillaries, thus creating an extracardiac right-to-left shunt. Radiographically, pulmonary AVMs appear as round, oval, or scalloped homogeneous nodules or masses with feeding arteries and draining veins. They are most common in the lower lobes and in the periphery of the lung. It is important to measure the diameter of the feeding artery, since embolization of the arteriovenous malformation is possible only if the diameter exceeds 3 mm.]
What is the treatment for a non-seminoma mediastinal germ cell tumor?
- Chemotherapy (cisplatin, bleomycin, VP-16)
- Surgery for residual disease
[UpToDate: For patients with a mediastinal nonseminomatous GCT, we recommend four cycles of chemotherapy as the initial therapy, rather than surgery or RT (Grade 1A). We suggest VIP rather than BEP because of the increased risks of bleomycin pulmonary toxicity should surgery eventually be required.
For patients with a residual mediastinal mass following initial chemotherapy, we recommend complete surgical resection if technically feasible (Grade 1A). If viable malignancy is identified, two additional cycles of VIP chemotherapy should be given.]
What kind of pleural fluid has <1,000 WBC, a pH of 7.45-7.55, a pleural fluid protein to serum ratio <0.5, and a pleural fluid LDH to serum ratio <0.6?
Transudative pleural fluid
[UpToDate: Transudates result from imbalances in hydrostatic and oncotic pressures in the chest, as occur with CHF and nephrosis, or conditions external to the pleural space. Examples of the latter include movement of fluid from the peritoneal, cerebrospinal, or retroperitoneal spaces, or from iatrogenic causes, such as crystalloid infusion through a central venous catheter that has migrated into the mediastinum or pleural space. Nevertheless, transudates have a limited number of diagnostic possibilities that can usually be discerned from the patient’s clinical presentation.
According to the traditional Light’s Criteria Rule, if at least one of the following three criteria (ie, component tests of the rule) is fulfilled, the fluid is defined as an exudate:
- Pleural fluid protein/serum protein ratio greater than 0.5, or
- Pleural fluid LDH/serum LDH ratio greater than 0.6, or
- Pleural fluid LDH greater than two-thirds the upper limits of the laboratory’s normal serum LDH]
Where do lung abscesses usually occur?
Superior segment of the right lower lobe
[UpToDate: Most patients with lung abscesses, and nearly all with lung abscesses due to anaerobic bacteria, present with indolent symptoms that evolve over a period of weeks or months.
Anaerobic infection: The characteristic features suggest pulmonary infection, including fever, cough, and sputum production. Evidence of chronic systemic disease is usually present, with night sweats, weight loss, and anemia. Patients may seek medical attention for these systemic symptoms, hemoptysis, or pleurisy. Nearly all patients have fever, but virtually none have shaking chills or true rigors. Most patients are aware of putrid or sour-tasting sputum. Lung abscesses due to S. milleri behave like anaerobic infections but do not have putrid sputum unless the organism occurs in a mixed infection including anaerobes.
Typical findings on physical examination are gingival crevice disease, the stigma of associated conditions that compromise consciousness or cause dysphagia, fever, and abnormal lung sounds reflecting a pleural effusion and/or parenchymal disease. Chest radiographs usually show infiltrates with a cavity, frequently in a segment of the lung that is dependent in the recumbent position (eg, the superior segment of a lower lobe or a posterior segment of the upper lobes). The approach should include evaluation of the expectorated secretions for evidence of putrid odor.
Although the majority of lung abscesses are caused by anaerobic bacteria, aerobic bacteria such as microaerophilic streptococci (eg, S. milleri), Staphylococcus aureus, and Klebsiella pneumoniae may also cause lung abscesses.]
What is the most common mediastinal neurogenic tumor?
Neurolemmoma (Schwannoma)
[UpToDate: Neurogenic tumors of the mediastinum represent 19-39% of all mediastinal tumors and develop from mediastinal peripheral nerves, sympathetic and parasympathetic ganglia, and embryonic remnants of the neural tube. They are most frequent in the posterior compartment of the mediastinum, where they can cause neurologic symptoms by compression
A variety of benign and malignant tumors of peripheral nerve origin can occur in the mediastinum, among which benign schwannoma (neurilemmoma) is the most common. Mediastinal benign schwannoma originates from Schwann cells and affects patients of both sexes predominantly in the third and fourth decade of life. These tumors can be multiple in patients with neurofibromatosis.]
Spontaneous pneumothorax usually occurs on which side?
Right side
[Note: Unable to corroborate this.]